Skip to main content
Top

SCN5A Cardiomyopathy: from Ion Channel Dysfunction To Clinical Disease

  • Open Access
  • 01-12-2025
  • Cardiomyopathy
  • Myocardial Disease (A Abbate and M Merlo, Section Editors)
Published in:

Abstract

Purpose of Review

Although SCN5A variants are an established cause of arrhythmia and conduction disease, their association with dilated cardiomyopathy (DCM) is less studied. This review summarizes recent insights into SCN5A-related cardiomyopathy, focusing on genotype-phenotype correlations, overlap with arrhythmia, and implications for management.

Recent Findings

Both gain- and loss-of-function SCN5A variants are associated with cardiomyopathy, found in 0.5–0.9% of DCM cases. Presentation ranges from isolated DCM to overlap phenotypes, in both pediatric and adult patients. High variability and intrafamilial heterogeneity suggest pleiotropic effects and variable penetrance. High prevalence of arrhythmias and conduction disease suggests the DCM phenotype may be mediated by electrical disturbances. However, functional studies and cases without prior arrhythmia suggest SCN5A variants may directly contribute to structural myocardial changes.

Summary

SCN5A-related cardiomyopathy is a rare disorder at the intersection of structural and electrical heart disease. Genotype-informed strategies, including arrhythmia management, and early cascade genetic screening are clinically relevant. Further research should address SCN5A-specific risk management in DCM patients.
Title
SCN5A Cardiomyopathy: from Ion Channel Dysfunction To Clinical Disease
Authors
Astrid B.M. Heymans
Lorenzo Bianchi
Paul G.A. Volders
Saskia N. van der Crabben
Job A.J. Verdonschot
Publication date
01-12-2025
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 1/2025
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-025-02298-5
This content is only visible if you are logged in and have the appropriate permissions.

Next-generation MRI contrast agents: preparing the field (Link opens in a new window)

New MRI contrast agents are reshaping diagnostic imaging, promising lower gadolinium exposure amid evolving practice guidelines. How can you optimise contrast selection, dosing, and patient care in this rapidly advancing field?

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Bayer HealthCare Pharmaceuticals Inc.
Learn more Link opens in a new window
Image Credits
Abstract graphic of layered, concentric circular shapes in bright green, pink, blue, and purple on a dark blue background. The rings and segments form a complex radial pattern without text/© Springer Health+ IME